ViiV Healthcare announced that an independent data safety monitoring board (DSMB) recommended the early unblinding of data from the HIV Prevention Trials Network 084 trial of the investigational, long-acting injectable cabotegravir for HIV prevention in women.
Med Ad News spoke with Christian Heidbreder, Ph.D., Chief Scientific Officer of Indivior Inc., about some of the barriers to patients seeking treatment for opioid use disorder, how to integrate treatment for opioid use disorder and infectious disease services, and the company’s efforts to provide treatments for those struggling with the disorder.
Intra-Cellular Therapies Inc.’s lead drug failed to meet the main goal of a late-stage study in patients with major depressive episodes associated with bipolar disorder.
Neos Therapeutics Inc’s drug to treat a common type of childhood behavioral disorder was approved by the U.S. Food and Drug Administration, making it the first of its kind to […]